High-Dose Chemotherapy and Autologous Stem Cell Transplant in Older Patients with Lymphoma Review uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Hematopoietic Stem Cell Transplantation
  • Lymphoma

abstract

  • High-dose chemotherapy followed by autologous hematopoietic stem cell transplant (HDT/ASCT) can improve survival in patients with lymphoma. Limited experience is available on the safety and efficacy of HDT/ASCT in elderly patients. In this article, we review the published data on the role of HDT/ASCT in management of lymphoma in older patients. Based on available data, evaluation of comorbidities, functional status, and comprehensive geriatric assessment (CGA) will help identify those who can benefit most from this intervention. Prospective clinical trials focusing on HDT/ASCT in older patients with lymphoma are needed to establish optimal management protocols in this select population.

publication date

  • September 27, 2015

Research

keywords

  • Review

Identity

Language

  • eng

PubMed Central ID

  • PMC5542393

Digital Object Identifier (DOI)

  • 10.1007/s11912-015-0465-x

PubMed ID

  • 26201264

Additional Document Info

start page

  • 42

volume

  • 17

number

  • 9